Launch of Yourgene® Insight DPYD assay

AI SummaryClose X

Novacyt S.A. has launched its enhanced Yourgene® Insight DPYD assay, a genotyping test designed to identify cancer patients at risk of severe side effects from 5-Fluorouracil chemotherapy due to DPD deficiency. This updated assay now detects 19 variants, including the 14 recommended by updated guidelines from organizations like AMP and ACMG, an increase from the previous six. The test, initially for Research Use Only, aims to provide safer, more personalized treatment decisions by allowing for adjustments to chemotherapy regimens, a critical step as over two million patients globally are treated with fluoropyrimidines annually, with 10-20% experiencing severe adverse reactions.

Disclaimer*

UK 100

Latest directors dealings